Summary by Moomoo AI
GSK announced that the European Commission has approved a new single-vial, fully liquid presentation of Menveo vaccine for protection against invasive meningococcal disease (IMD). The vaccine is licensed for active immunization of individuals from age 2 and above, offering healthcare providers a simplified administration process that eliminates the need for reconstitution.The approval was supported by two positive Phase IIb trials demonstrating comparable immunogenicity, tolerability, and safety profile to the existing lyophilised/liquid formulation. The vaccine targets bacterial serogroups A, C, W and Y, addressing a serious illness that can cause life-threatening complications with up to one in six mortality rate among infected individuals.Since its initial approval in 2010, Menveo has been distributed globally with over 82 million doses worldwide, including 6 million doses in European countries since 2017. The original presentation requiring reconstitution remains unaffected by this new authorization.
